Olga A. Fomicheva

Olga A. Fomicheva

Auto-generated profile, based on publicly available information

Olga A. Fomicheva

National Medical Research Center for Cardiology named after academician Yevgeniy Chazov

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OFO. A. Fomicheva
O. A. Fomicheva
TBTatyana Balakhonova
Tatyana Balakhonova
OPO. A. Pogorelova
O. A. Pogorelova
МТМ. И. Трипотень
М. И. Трипотень
FSF. F. Shingareeva
F. F. Shingareeva
ENE. L. Nassonov
E. L. Nassonov
Aim. To assess plaque burden according to peripheral artery ultrasound examination in patients with rheumatoid arthritis (RA) with low and moderate disease activity in comparison with the coronary artery condition.Material and methods. The study included 64 patients, of which 43 patients with an established diagnosis of RA and 21 patients with coronary artery disease (CAD) without RA (comparison group). All patients underwent a clinical and paraclinical examination to verify myocardial ischemia and/or CAD according to the 2020 national guidelines, as well as a carotid and femoral artery ultrasound (the latter, only for patients with RA) with determination of plaque burden.Results. In patients with RA in combination with CAD, plaque burden is higher than in patients with RA without coronary artery disease regarding the carotid plaque number 4,0 [4,0; 5,0]/2,0 [1,0; 3,5], proportion of maximum stenosis 35,0 [35,0; 45,0]/30,0 [25,0; 35,0] and the proportion of total stenosis 120,0 [110,0; 152,5]/85,0 [40,0; 110,0]. Three or more carotid plaques determine significant coronary atherosclerosis in RA. In RA patients with CAD, the combination of caro­tid and femoral plaques is associated with significant coronary atherosclerosis in 75% of cases. In a comparative analysis of patients with RA CAD+/RA CAD-, no significant differences were found in the main cardiovascular risk factors, lipid, and inflammatory parameters. When comparing the plaque burden indicators, the severity of coronary atherosclerosis was not revealed between RA patients with CAD+ and the comparison group.Conclusion. Determining the peripheral plaque burden parameters increases the clinical significance of ultrasound as a stage of non-invasive CAD diagnosis in RA.

5 August 2026 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ENE. I. Nasonov
E. I. Nasonov
OFO. A. Fomicheva
O. A. Fomicheva
ABA. A. Baranov
A. A. Baranov
TVTatyana Popkova V.
Tatyana Popkova V.
MSMikhail Samsonov
Mikhail Samsonov
МСМ. Ю. Самсонов
М. Ю. Самсонов
Although the role of inflammation in the development of atherosclerotic vascular lesions, as the leading form of organ pathology in the cardiovascular diseases (CVD), has been discussed for more than 100 years, only in the last 30 years has the “inflammatory” theory of atherosclerosis begun to be considered as one of the most important areas of fundamental and clinical research in cardiology and other areas of biology and medicine. According to modern concepts, chronic low-grade inflammation, the development of which is associated with uncontrolled activation of innate and acquired immunity, plays a fundamental role at all stages of the progression of the atherosclerotic process associated with CVD. The fundamental contribution of inflammation to the development of atherosclerotic vascular lesions has drawn attention to the similarity of the mechanisms of immunopathogenesis of atherosclerosis in CVD and rheumatoid arthritis, and subsequently other systemic immune-mediated rheumatic diseases (IMRDs). In the spectrum of numerous inflammatory mediators and “immune” cells involved in the immunopathogenesis of atherosclerosis in both CVD and IMIRD, the central place is occupied by “pro-inflammatory” cytokines such as interleukin (IL) 1, IL-6, tumor necrosis factor α, as well as IL-17 and interferon type I, which closely interact within the “cytokine network”. IL-6, which occupies a central place in the development of many IMIDs, on the one hand, and CVDs associated with atherosclerotic vascular lesions, on the other hand, is attracting special attention as a promising therapeutic “target”: coronary heart disease, acute coronary syndrome, peripheral arterial disease, ischemic stroke, heart failure, and others. Of particular importance is the fact that hyperproduction of IL-6 plays a significant role in the development of a wide range of cardiometabolic diseases, including type 2 diabetes mellitus, obesity, chronic kidney disease, metabolically associated fatty liver disease, associated with the development of atherosclerotic vascular lesions. Data were obtained indicating the important clinical significance of IL-6 for predicting the risk of premature mortality and other cardiovascular complications both in the general population of conditionally “healthy” people and in patients with various manifestations and forms of CVD. Several biologics, which are monoclonal antibodies specific for both IL-6R and IL-6 itself, have been developed. Several randomized clinical trials have recently been initiated to study the efficacy and safety of new anti-IL-6 mAbs: ziltivekimab, clazakizumab, and Pacibekitug (TOUR006) in patients with coronary artery disease, heart failure, and chronic kidney disease. The article will review new data regarding the pathogenetic and clinical significance of IL-6 and the prospects for IL-6 inhibition as a component of anti-inflammatory therapy for CVD.

14 February 2026 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
ZSZulfiya N. Sukmarova
Zulfiya N. Sukmarova
RGRimma G. Gulyan
Rimma G. Gulyan
ATAnna V. Torgashina
Anna V. Torgashina
TSTatiana S. Sukhinina
Tatiana S. Sukhinina
EAEvgeniia S. Aronova
Evgeniia S. Aronova
ASAnna S. Starkova
Anna S. Starkova
According to modern concepts, pericarditis is a more complex condition than was previously thought. A clinical case is presented in which, as often happens, the symptoms of pericarditis were mistaken for radicular syndrome and an acute respiratory viral infection; therefore, adequate treatment was not initially administered. It led to hyperactivation of autoinflammation, which colchicine and nonsteroidal anti-inflammatory drugs failed to control, and required high doses of glucocorticosteroids. However, at this stage, probably due to the destruction of cardiomyocytes, the activation of the autoimmune processes has already occurred, which resulted in the relapsing disease. Further management was associated with challenges in differential diagnosis, decision-making regarding the use of reserve drugs – interleukin-1 inhibitors and immunoglobulin – and the treatment of complications. It took about 1.5 years to achieve stable remission, made possible by the coordinated work of the cardiology and rheumatology centers.

1 October 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
OFO A Fomicheva
O A Fomicheva
TVTatyana Popkova V.
Tatyana Popkova V.
EGElena Gerasimova
Elena Gerasimova
LKL B Krougly
L B Krougly
OPO A Pogorelova
O A Pogorelova
MTM I Tripoten
M I Tripoten
Aim of the study: Determine in prospective observation study the factors of progression of atherosclerosis in pts with rheumatoid arthritis (RA) during 3 yrs. Matherial and methods: This prospective study included 124 patients with RA and suspected ischemic heart disease (IHD), the average age was 58 [52; 63] years. Follow-up period was 3 years (37.5 moths). All RA pts were examined and had treatment, according to European and National guidelines for the diagnosis and treatment of stable CAD (2013) and EULAR for RA (2016). Carotid ultrasound and coronary angiography were also completed. In course of all RA pts the following risk factors were assessed: arterial hypertension (AH), smoking, overweightbody (BMI), heredity for cardiovascular diseases (CVD), diabetes mellitus (DM), dyslipidemia (DLP). The laboratory studies were: CBC and total cholesterol (TC), HDL-C, LDL-C, TG, highly sensitive C-reactive protein (hs-CRP), RA detected activity markers: rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (ACCP), index DAS28. Pro-inflammatory cytokines -interleukin (IL) -1-beta, IL-6, tumor necrosis factor alpha (TNF alpha) were assessed in single RA pts once after 3 years of observation. Results: The median duration of RA in inclusion in the study was 11 years, the DAS28 index was 3.8 points (middle degree of activity). DLP was detected in 41% RA pts. DM was in 13% pts. In RA pts, initially atherosclerotic plaques with stenosis of the carotid arteries (CA) 20% or more in 94 pts (77%) were revealed, in 3 of them CA stenosis exceeded 50%. 90 RA pts (72%) were examined again. 21 pts had signs of progressing atherosclerosis marked in CA and/or coronary arteries: 12 (13%) RA patients had only progression of atherosclerosis of CA, 7 (8%) - only progression of atherosclerosis of coronary arteries, 2 (2%) had both progression CA and coronary arteries. There are 2 formed subgroups of RA pts: Gr1 with the progression of atherosclerosis (n=21) and Gr 2 without progression of atherosclerosis (n=69). There are no differences between groups of risk factors of atherosclerosis development age, AH, BMI, lipids,TG, hs CRP, index DAS28. Following rick factors: smoking (n=12 (57%) vs n=21 (30%)), heredity for CVD (n=11 (52%) vs n=17 (25%)), RA duration (13 yrs [10; 18] vs 12 years [6; 18]) were often revealed among pts of Gr 1. All differences p>0.05 Immunological data TNF alfa level, (8,08 [2,3; 8,44] pg/ml vs 1,22 [0,13; 8,00] pg/ml), IL-1β level, 3,97 [3,56; 4,10] pg/ml vs 3,52 [0,30; 4,53] pg/ml, and IL-6 level 3,50 [2,92; 5,76] pg/ml vs 2,52 [0,92; 4,36] pg/ml were significant higher in Gr1 than in Gr2. All differences was p>0.05. Conclusion: The progression of atherosclerosis in RA with a low and moderate degree of activity of the disease occurs despite antirheumatic and lipid-lowering therapy. The development of atherosclerosis in this disease is defined by lipid, inflammatory and immunological disorders. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Russion National Cardiology Research Center Ministry of Health of Russion Federation

11 December 2020 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
ОПО.а. Погорелова
О.а. Погорелова
ОФО.а. Фомичева
О.а. Фомичева
МТМ.и. Трипотень
М.и. Трипотень
ЛКЛ.б. Круглый
Л.б. Круглый
EGElena Gerasimova
Elena Gerasimova
TBTatyana Balakhonova
Tatyana Balakhonova
Введение. Ревматоидный артрит (РА) ассоциируется с повышенным риском сердечно-сосудистых заболеваний по сравнению с общей популя- цией. Для понимания роли системного воспаления в развитии сердечно-сосудистых катастроф у больных РА принципиальное значение имеет концепция о сходстве патогенетических механизмов аутоиммунного воспаления и атеросклероза. Ультразвуковое исследование с контраст- ным усилением (КУУЗИ) позволяет выявить неоваскуляризацию (НВ) атеросклеротической бляшки (АСБ), что отражает воспаление в бляшке и свидетельствует о ее нестабильности. Материал и методы. Был обследован 21 пациент с РА (7 мужчин и 14 женщин) в возрасте 61 (58; 65) год, длительность заболевания 7 (3; 16) лет. КУУЗИ сонных артерий (СА) проводили на ультразвуковой системе Philips IU22 c линейным датчиком 3–9 МГц, с внутривенным введением контрастного препарата «Соновью». Степень НВ бляшки оценивали как 0 — отсутствие НВ, 1 — слабая НВ, 2 — выраженная НВ, 3 — НВ при наличии пульсирующего сосуда. Результаты. У всех больных РА была выявлена НВ бляшки сонной артерии, при этом слабая степень НВ была выявлена в 7 случаях (33,3%), выраженная степень НВ — в 14 (66,7%). При проведении корреляционного анализа по Спирмену выявлена прямая уме- ренная корреляция между степенью НВ и холестерином липопротеидами низкой плотности (ХС ЛПНП) (R = 0,46, р = 0,04), прямая заметная корреляция между степенью НВ и триглицеридами (R = 0,56, р = 0,01), обратная заметная корреляция между степенью НВ и холестерином липопротеидами высокой плотности (R = -0,52, р = 0,02), умеренная корреляция между НВ бляшки и длительностью РА (R = 0,43, р = 0,052), заметная корреляция между НВ и наличием специфических антител к циклическому цитруллинированному пептиду (R = 0,57, р = 0,0068). Не было выявлено взаимосвязи между степенью НВ и уровнем высокочувствительного С-реактив- ного белка, скоростью оседания эритроцитов, холестерина, индексом активности РА DAS28 и наличием специфических антител ревматоидного фактора IgM. Заключение. КУУЗИ продемонстрировало наличие преимущественно высокой степени неоваскуляризации АСБ СА у пациентов с РА. КУУЗИ СА является доступным методом выявления нестабильности атеросклеротической бляшки СА у пациентов с РА с целью ранней профилактики и предотвращения сердечно-сосудистых осложнений Introduction. Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease compared to the general population. Similarity of the pathogenetic mechanisms of autoimmune inflammation and atherosclerosis is fundamentally important for understanding the role of systemic inflammation in the development of cardiovascular complications in RA. Contrast-enhanced ultrasound (CEUS) reveals neovascularization of an atherosclerotic plaque, which reflects inflammation in the plaque and indicates its vulnerability. Material and methods. We examined 21 patients with RA (7 males) with the median age of 61 [58; 65] years old and the median RA duration of 7[3; 16] years. CEUS of the carotid arteries was performed with the PHILIPS IU22 ultrasound system and 3-9 MHz linear array transducer. Ultrasound contrast agent SonoVue was administered intravenously. The degree of carotid intraplaque neovascularization was visually assessed on a scale from 0 to 3. Grade 0 represented no visible neovascularization, grade 1 — limited to moderate neovascularization, grade 2 extensive appearance of neovascularization, grade 3 — presence of a pulsating arterial vessel within the plaque (Shah et al. 2007). The association between the degree of neovascularization, biochemical parameters and RA duration was assessed with the Spearman’s correlation coefficient. Results. All patients with RA were found to have carotid intraplaque neovascularization. Grade 1 of neovascularization was detected in 33.3 % of patients and grade 2 was detected in 66.7%. The degree of neovascularization was positively associated with the LDL-C level (R = 0,46, p = 0,04), and the TG level (R = 0,56, p = 0,01) and negatively associated with the HDL-C level (R = -0,52, p = 0,02). The degree of neovascularization was also associated with RA duration (R = 0,43, p = 0,052) and the presence of antibodies...

31 October 2026 in Rheumatology Science and Practice
Verified
Journal Article
Closed access
ENE. L. Nasonov
E. L. Nasonov
SBSergey Boytsov
Sergey Boytsov
OFO. A. Fomicheva
O. A. Fomicheva
TVTatyana Popkova V.
Tatyana Popkova V.
AKAlesya Alexandrovna Klimenko
Alesya Alexandrovna Klimenko
MSMikhail Samsonov
Mikhail Samsonov
Among the multidisciplinary medical issues facing rheumatology as a branch of internal medicine, a central place is occupied by cardiovascular diseases (CVD) associated with atherosclerotic vascular disease (ASCVD); these – as in the general population – are the leading causes of mortality and the most common forms of comorbidity. Chronic inflammation, regarded as a central mechanism in the pathogenesis of both systemic autoimmune rheumatic diseases (SARDs) and CVDs, is associated with shared genetic and environmental factors. Alongside ASCVD and peripheral artery disease, heart failure and arterial hypertension are common forms of comorbid cardiovascular pathology in SARDs, whereas pericarditis, endocarditis, other forms of valvular heart disease, arrhythmias, coronary vasculitis, pulmonary arterial hypertension, myocarditis, inflammatory cardiomyopathy, and aortic aneurysm and dissection are considered systemic manifestations of SARDs. Data from large-scale epidemiological population studies, registries, databases, and their meta-analyses regarding CVD risk in SARDs indicate an increased risk of cardiovascular pathology in patients with autoimmune diseases – particularly those under the age of 45 – which is associated with a higher need for hospitalization and increased mortality. The development of ASCVD in patients with SARDs is associated not only with traditional cardiovascular risk factors but also with clinical parameters and laboratory and instrumental biomarkers reflecting immune dysregulation, inflammatory activity, and endothelial dysfunction. Chronic subclinical (low-grade) inflammation plays a fundamental role at all stages of ASCVD progression: vascular endothelial dysfunction; induction of endothelial cell apoptosis; synthesis and modification of lipoproteins, including low-density lipoproteins and apolipoprotein(a); formation of “foam” cells; rupture of the atherosclerotic plaque; and development of atherothrombosis. A wide range of anti-inflammatory drugs with diverse mechanisms of action has currently been developed for the treatment of SARDS; their efficacy is linked to the inhibition of the synthesis or signaling of pro-inflammatory cytokines, and the cardiovascular effects of these drugs in the context of SARDS and cardiovascular diseases are the subject of intensive research. A wide range of clinical and fundamental issues common to both cardiology and rheumatology has led to the emergence of a new field – cardiorheumatology – which integrates these issues within a multidisciplinary specialty dedicated to the comprehensive study of the role of inflammation in the development of cardiovascular and rheumatic diseases. In Russia, the study of issues in cardiorheumatology – using rheumatic heart disease as a model – began as early as the mid20th century. Academician A.I. Nesterov was a pioneer in this field, playing a foundational role in the establishment of the Institute of Rheumatology (1958) and the cardiorheumatology service in Russia; he was later succeeded in this work by Academicians E.I. Chazov and V.A. Nasonova. Global experience and Russia’s rich traditions in studying the immunopathology of cardiovascular diseases and SARDs create a solid foundation for expanding multidisciplinary research in the field of cardiorheumatology in Russia.